1. Home
  2. ASH vs TRVI Comparison

ASH vs TRVI Comparison

Compare ASH & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ashland Inc.

ASH

Ashland Inc.

HOLD

Current Price

$68.18

Market Cap

3.1B

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$19.20

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASH
TRVI
Founded
1924
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
ASH
TRVI
Price
$68.18
$19.20
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$65.57
$21.55
AVG Volume (30 Days)
846.9K
2.9M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
3.38%
N/A
EPS Growth
N/A
31.91
EPS
0.08
N/A
Revenue
$1,824,000,000.00
N/A
Revenue This Year
$2.58
N/A
Revenue Next Year
$4.28
N/A
P/E Ratio
$854.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$46.30
$6.55
52 Week High
$69.11
$20.15

Technical Indicators

Market Signals
Indicator
ASH
TRVI
Relative Strength Index (RSI) 63.04 60.37
Support Level $58.70 $10.07
Resistance Level N/A $20.15
Average True Range (ATR) 1.82 1.30
MACD 0.03 -0.13
Stochastic Oscillator 83.53 68.09

Price Performance

Historical Comparison
ASH
TRVI

About ASH Ashland Inc.

Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: